Aligos Therapeutics Net Income Over Time
| ALGS Stock | USD 8.06 0.53 6.17% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Aligos Therapeutics Performance and Aligos Therapeutics Correlation. Is there potential for Biotechnology market expansion? Will Aligos introduce new products? Factors like these will boost the valuation of Aligos Therapeutics. If investors know Aligos will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Aligos Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (13.54) | Revenue Per Share | Quarterly Revenue Growth (0.42) | Return On Assets | Return On Equity |
Investors evaluate Aligos Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Aligos Therapeutics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Aligos Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Aligos Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Aligos Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Aligos Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income Analysis
Compare Aligos Therapeutics and related stocks such as Mersana Therapeutics, Kezar Life Sciences, and FibroGen Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MRSN | (16.4 M) | (16.4 M) | (16.4 M) | (16.4 M) | (16.4 M) | (16.4 M) | (13.7 M) | (38.7 M) | (64.3 M) | (28.2 M) | (88 M) | (170.1 M) | (204.2 M) | (171.7 M) | (69.2 M) | (62.3 M) | (65.4 M) |
| KZR | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (8.5 M) | (23.2 M) | (31.5 M) | (39 M) | (54.6 M) | (65.3 M) | (101.9 M) | (83.7 M) | (75.4 M) | (71.6 M) |
| XFOR | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (23 M) | (33.9 M) | (43 M) | (56.6 M) | (62.1 M) | (88.7 M) | (93.9 M) | (101.2 M) | (37.5 M) | (33.7 M) | (35.4 M) |
| TPST | (2.7 M) | (2.7 M) | (13.5 M) | (29 M) | (49.5 M) | (73.2 M) | (82.3 M) | (84.6 M) | (27.2 M) | (44.6 M) | (19.1 M) | (28.3 M) | (35.7 M) | (29.5 M) | (41.8 M) | (37.7 M) | (39.5 M) |
| BRNS | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (17.7 M) | (50.9 M) | 5.3 M | (73.3 M) | (61.1 M) | (55 M) | (57.7 M) |
| OKUR | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (39.8 M) | (29.5 M) | (35.3 M) | (52.7 M) | (47.4 M) | (49.8 M) |
| CVM | (2.9 M) | (15.5 M) | (9.2 M) | (27.4 M) | (34.7 M) | (11.5 M) | (14.4 M) | (31.8 M) | (24.7 M) | (32.2 M) | (39.2 M) | (38.3 M) | (32.4 M) | (26.9 M) | (25.4 M) | (22.9 M) | (21.7 M) |
| INMB | (48.9 K) | (48.9 K) | (48.9 K) | (48.9 K) | (48.9 K) | (48.9 K) | (277 K) | (831 K) | (12.4 M) | (7.7 M) | (12.1 M) | (30.3 M) | (28.6 M) | (30 M) | (42.1 M) | (37.9 M) | (36 M) |
| SKYE | 4.5 K | 4.5 K | 4.5 K | (120.4 K) | (2.7 M) | (4.8 M) | (3.2 M) | (3.1 M) | (19.2 M) | 1.1 M | (6.6 M) | (8.5 M) | (19.5 M) | (37.6 M) | (26.6 M) | (23.9 M) | (22.7 M) |
Aligos Therapeutics and related stocks such as Mersana Therapeutics, Kezar Life Sciences, and FibroGen Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Aligos Therapeutics financial statement analysis. It represents the amount of money remaining after all of Aligos Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Aligos Therapeutics | ALGS |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | One Corporate Drive, |
| Exchange | NASDAQ Exchange |
USD 8.06
Additional Tools for Aligos Stock Analysis
When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.